Gsk (GLAXF) Free Cash Flow (2009 - 2026)

Gsk's Free Cash Flow history runs 18 years deep, the most recent figure standing at $2.1 billion for Q1 2026.

• In Q1 2026, Free Cash Flow rose 11.44% year-over-year to $2.1 billion; the TTM figure through Mar 2026 stood at $5.6 billion (down 19.02% YoY), while the FY2025 annual figure was $8.4 billion, up 27.92% from the prior year.
• Free Cash Flow was $2.1 billion for Q1 2026 at Gsk, down from $2.7 billion in the prior quarter.
• In the past five years, Free Cash Flow ranged from a high of $4.3 billion in Q4 2024 to a low of -$361.3 million in Q4 2022.
• Historically, Free Cash Flow has averaged $1.5 billion across 5 years, with a median of $525.9 million in 2023.
• The sharpest annual moves came in 2022 and 2023: Free Cash Flow slumped 110.42% in 2022, then soared 1206.61% in 2023.
• A 5-year view of Free Cash Flow shows it stood at -$361.3 million in 2022, then jumped by 1206.61% to $4.0 billion in 2023, then gained by 6.59% to $4.3 billion in 2024, then slumped by 35.7% to $2.7 billion in 2025, then declined by 22.71% to $2.1 billion in 2026.
• The last three Free Cash Flow figures came in at $2.1 billion (Q1 2026), $2.7 billion (Q4 2025), and $419.7 million (Q3 2025), per Business Quant data.